- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01703156
Low Risk Acute Coronary Syndrome (LOW ACT)
April 10, 2017 updated by: Mazen Abu-Fadel, M.D., University of Oklahoma
Stress Testing Versus Non-Stress Testing Based Strategy in Patients Hospitalized With Low-Risk Acute Coronary Syndromes: A Randomized, Single-Center Pilot Study
A large number of patients are diagnosed with low risk ACS, and these individuals are at significant cardiovascular risk.
Though guidelines recommend stress testing to manage low risk ACS patients, evidence supporting this recommendation is not based on trials examining this population.
A well-designed, randomized trial is warranted to determine if stress testing is useful in managing low risk ACS.
If medical therapy alone is equivalent as the investigators hypothesize, healthcare expenditures could be reduced and patients may not be exposed to the harms associated with more invasive cardiac testing such as coronary angiography.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Veteran's Affairs Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- TIMI score < or = to 2(12)
- TIMI risk score of 3 with no known CAD, greater than 50% in one or more vessels
- Normal cardiac biomarkers (3 sets over 12-88 hours)
- No evidence of acute ischemia on electrocardiograms
- Normal ejection fraction (>40%) on echocardiography
- Age 30-75
- Ability to complete noninvasive stress test
- Ability to provide informed consent
Exclusion Criteria:
- Presence of another medical condition to explain chest pain or non-cardiac chest pain (i.e. pneumonia, costochondritis)
- Any patient who is initially classified as low risk but whom develops recurrent symptoms of ischemia, hemodynamic instability, or arrhythmias attributable to ischemia
- Evidence of ischemia on electrocardiogram
- Abnormal cardiac biomarkers
- History of medical noncompliance or social circumstances preventing compliance
- Life span estimated at <1 year
- Pregnancy
- Refusal to sign consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Non-Stress Group
Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins.
The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician.
Statins will be initiated irrespective of LDL unless contraindicated.
Clopidogrel will be taken for at least one month and ideally up to one year.
Sublingual nitroglycerin will be provided to all patients.
Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion.
If a patient has contraindications to any medications, they will not be administered.
If a statin contraindication exists, other cholesterol-lowering medications may be administered.
Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
|
|
|
ACTIVE_COMPARATOR: Stress Group
Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins.
Statins will be initiated irrespective of LDL unless contraindicated.
Clopidogrel will be taken for at least one month and ideally up to one year.
Sublingual nitroglycerin will be provided to all patients.
Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion.
If a statin contraindication exists, other cholesterol-lowering medications may be administered.
All patients will undergo noninvasive stress testing.
Results of individual stress tests will be reviewed by a cardiologist.
Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered.
Likewise, medical treatment may be adjusted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of all-cause mortality, hospitalization for UA/NSTEMI or STEMI, and urgent revascularization
Time Frame: one year
|
Primary endpoints include the composite of all-cause mortality, hospitalization for Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) or ST-Elevation Myocardial Infarction (STEMI), and urgent revascularization (coronary artery bypass grafting or percutaneous coronary intervention).
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary endpoints will include mortality, UA/NSTEMI or STEMI, coronary revascularization, unplanned diagnostic coronary angiography, noninvasive stress testing, medication adjustments, and medication side effects.
Time Frame: one year
|
Secondary endpoints will include: mortality, UA/NSTEMI or STEMI, coronary revascularization, unplanned diagnostic coronary angiography, noninvasive stress testing, medication adjustments, and medication side effects.
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mazen S Abu-Fadel, MD, FACC, FSCAI, OUHSC and VAMC OKC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (ACTUAL)
July 1, 2012
Study Completion (ACTUAL)
July 1, 2012
Study Registration Dates
First Submitted
October 3, 2012
First Submitted That Met QC Criteria
October 9, 2012
First Posted (ESTIMATE)
October 10, 2012
Study Record Updates
Last Update Posted (ACTUAL)
April 12, 2017
Last Update Submitted That Met QC Criteria
April 10, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Low Risk ACS
- IRB#14542 (OTHER: University of Oklahoma Health Sciences Center Institutional Review Board)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Risk Acute Coronary Syndrome
-
Shenyang Northern HospitalNot yet recruitingPercutaneous Coronary Intervention | Acute Coronary Syndromes | High Bleeding Risk | Anticoagulant Therapy
-
Shenyang Northern HospitalChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS) | High Bleeding Risk(HBR)China
-
Xijing HospitalNot yet recruitingPercutaneous Coronary Intervention | Acute Coronary Syndromes | Chronic Coronary Syndrome | High Risk PatientChina
-
Samsung Medical CenterNot yet recruitingHigh Bleeding Risk | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)Korea, Republic of
-
Instituto de Seguridad y Servicios Sociales de...National Council of Science and Technology, MexicoCompletedEndothelial Dysfunction | Cardiovascular Risk Factor | Coronary Syndrome, AcuteMexico
-
Federal State Budgetary Institution National Medical...Kemerovo Cardiology Center, Tarasov Roman Sergeevich; Tomsk National Research...RecruitingCoronary Syndrome, Acute, Non-ST Elevation, High Risk PatientsRussian Federation
-
Shenyang Northern HospitalChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS) | High Bleeding Risk (HBR)China
-
Shenyang Northern HospitalCompletedPercutaneous Coronary Intervention | Acute Coronary Syndromes | Clopidogrel Low ResponsivenessChina
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Ostfold Hospital TrustUniversity of TromsoCompletedLow Risk Birth; Births With Low Risk FactorNorway
Clinical Trials on No Stress Test
-
Medical University of South CarolinaCompletedTrauma | Posttraumatic Stress DisorderUnited States
-
Charite University, Berlin, GermanyCompleted
-
Johannes Gutenberg University MainzCompletedEndothelial FunctionGermany
-
Wingate InstituteTel Aviv UniversityCompleted
-
American College of RadiologyTerminatedCoronary Artery Disease | Chest Pain | Stable Angina Pectoris, CCS Class I to III | Angina EquivalentUnited States
-
Vanderbilt University Medical CenterMedtronicTerminatedExercise | Blood Pressure | PacemakerUnited States
-
Assaf-Harofeh Medical CenterInstitute of Physical Education and Sports SciencesUnknown
-
M.D. Anderson Cancer CenterUnknownLung CancerUnited States
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedHypoxia | Exercise | Sport PerformanceFrance
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedFirefighter | High Cardiovascular RiskFrance